跳至主要内容
临床试验/ACTRN12619001779167
ACTRN12619001779167尚未招募2 期

sing acamprosate to investigate a new target for treatment in Prader-Willi Syndrome

The University of Sydney0 个研究点目标入组 30 人开始时间: 2019年12月16日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 30 Years(—)
性别
All

入选标准

  • •1. Aged between 18 to 30 years.
  • •2. For participants with PWS, a confirmed genetic diagnosis of PWS.
  • •3. Provide voluntary, written informed consent (all participants). For participants with PWS, parent / legal guardian also provides voluntary, written consent.

排除标准

  • •1.Aged 17 years or younger and 31 years or older.
  • •2.MRI contraindications (e.g. pregnant, metal in the body, insulin pumps, vertigo, claustrophobia, etc)
  • •3.For PWS participants, comorbid psychiatric or neurological disorder that is not associated with PWS
  • •4.For controls, no known neurological, psychiatric, neurogenetic or serious medical condition
  • •5.Currently receiving treatment with a GABA compound
  • •6.For non-GABA compounds, concomitant drug use will be allowed as long as there has been stable dosing for at least 4 weeks prior to participation
  • •7.If evidence of potential renal failure creatine levels will be measured and participants with a creatinine clearance < 30 mL/min will be excluded.
  • •8.Known sulphite hypersensitivity
  • •9.Pregnant or breastfeeding women

研究者

相似试验